With proof-of-concept trials in ulcerative colitis ("UC") suggesting efficacy on a par Abivax's ABX464 looks a real alternative to approved therapies. A new class of oral drug releasing a natural inflammatory brake, ABX464 could alleviate the treatment failures and possibly safety issues of existing drugs. This would open a significant opportunity in a > $70bn market. We are optimistic that clinical studies planned for 2019E should confirm the UC results and may suggest efficacy in Crohn's Disea ....
22 Jan 2019
Getting a brake in inflammation
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Getting a brake in inflammation
Abivax SA (0RA9:LON) | 0 0 0.5% | Mkt Cap: 83.0m
- Published:
22 Jan 2019 -
Author:
Chris Redhead -
Pages:
20
With proof-of-concept trials in ulcerative colitis ("UC") suggesting efficacy on a par Abivax's ABX464 looks a real alternative to approved therapies. A new class of oral drug releasing a natural inflammatory brake, ABX464 could alleviate the treatment failures and possibly safety issues of existing drugs. This would open a significant opportunity in a > $70bn market. We are optimistic that clinical studies planned for 2019E should confirm the UC results and may suggest efficacy in Crohn's Disea ....